Shares of PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report) traded down 2.8% during trading on Friday . The stock traded as low as $1.72 and last traded at $1.73. 6,226 shares changed hands during trading, a decline of 29% from the average session volume of 8,831 shares. The stock had previously closed at $1.78.
PharmaCyte Biotech Stock Up 2.3 %
The stock has a 50 day moving average price of $1.79 and a two-hundred day moving average price of $2.03.
PharmaCyte Biotech Company Profile
PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.
Further Reading
- Five stocks we like better than PharmaCyte Biotech
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- 3 Key Stocks to Ride China’s Stimulus-Driven Growth
- Investing in Travel Stocks Benefits
- 3 Dividend Growth Stocks Set to Supercharge Your Portfolio
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
